Laurie Burlingame is a partner in the firm’s nationally recognized Life Sciences Practice Group. She represents private and public companies across the spectrum of the life sciences industry, including pharmaceuticals, medical devices, diagnostics and biological materials. Ms. Burlingame also represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments.

Ms. Burlingame often serves as outside general counsel to her clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including formation and founder issues, venture capital financings, public offerings, mergers and acquisitions, licensing transactions, strategic collaborations, commercial transactions, corporate governance and other general corporate matters.




A selection of Ms. Burlingame’s recent client representations includes:

Representative Matters

Repräsentative Angelegenheiten


Public Offerings
  • Zafgen, Inc. in its 2014 initial public offering (ranked the #8 life science IPO of 2014 by FierceBiotech)
  • Sage Therapeutics, Inc. in its 2014  initial public offering (ranked the #5 life science IPO of 2014 by FierceBiotech) 
  • Blueprint Medicines Corporation in its 2015  initial public offering (the largest IPO of a preclinical biotechnology company as of the date of the IPO’s closing)
  • Celyad S.A. in its 2015 U.S. initial public offering
  • Zafgen, Inc. in its 2015 follow-on offering
  • Sage Therapeutics, Inc. in its 2015 follow-on offering
Corporate Formations and Venture Capital Financings
  • Neon Therapeutics, Inc. in its formation and $55 million Series A Preferred Stock financing
  • Voyager Therapeutics, Inc. in its formation, $47 million Series A Preferred Stock financing and $60 million Series B Preferred Stock financing
  • Accelerator IV-New York Corporation and Accelerator IV-Seattle Corporation  in their formation and funding
  • Mevion Medical Systems, Inc. in connection with its up to $200 million Series F Preferred Stock financing
  • SetPoint Medical Corporation in connection with its $15 million Series C-1 Preferred Stock financing and $27 million Series C Preferred Stock financing
  • Scholar Rock, LLC in its Series A Preferred Unit financing
  • RaNA Therapeutics, LLC in its Series B Preferred Unit financing
  • iWalk, Inc. in its Series E Preferred Stock financing
  • NinePoint Medical, Inc. in its $34 million Series B Preferred Stock financing
Mergers and Acquisitions and Strategic Collaborations
  • Acetylon Pharmaceuticals, Inc. in its up to $1.7 billion collaboration and buyout option transaction with Celgene Corporation
  • Abide Therapeutics, Inc. in its collaboration and buyout option transaction with Celgene Corporation
  • ZOLL Medical Corporation in its acquisition of Advanced Circulatory Systems, Inc.
  • ZOLL Medical Corporation in its acquisition of the assets of Impact Instrumentation, Inc.
  • Nimbus Therapeutics, Inc. in connection with its innovative collaborations with Monsanto and Shire Plc
Professional Experience

Ms. Burlingame is a member of Women Entrepreneurs in Science and Technology (WEST) and through the firm is a member of the Massachusetts Biotechnology Council (MBC) and MassMEDIC. She is also a member of the American and Boston Bar Associations.

Ms. Burlingame is a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. Ms. Burlingame has served as a workshop speaker and advisor to the Boston Pipeline Angels for the past several years and has provided advice to start-up companies and entrepreneurs through participation in events and office hours held by Harvard University and M.I.T.


Ms. Burlingame has been the recipient of a writing award from the Boston Patent Law Association.

In The News

In den Nachrichten






J.D., 2006
Harvard Law School
M.B.A., 2003
Clark University
(concentration in accounting and finance)
A.M., Graduate School of Arts and Sciences, 2002
Harvard University
(concentration in molecular neuroscience)
B.A., 1999
Wellesley College

(summa cum laude, major in biology and psychology)



U.S. Patent and Trademark Office (USPTO)
Get In Touch
In Kontakt kommen
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers
Suche Andere Rechtsanwälte